The Effectiveness of Warfarin Versus Novel Oral Anticoagulants in Preventing Stroke Recurrence

• DOI: 10.22214/ijraset.2025.70681
• Publication Date: 2025-05-12T16:08:56Z
• Authors: Dr. Anuja Patil

Abstract: AIM:To study the effectiveness of warfarin VS novel oral anticoagulants in preventing stroke recurrance with atrial fibrillation ,CSVT and cardio embolic stroke MATERIALS AND METHODS: All the relevant and necessary data will be collected from patients record, lab reports, prescriptions and communicating with health care professionals RESULT:Out of 70 subjects screened according to inclusion and exclusion criteria, 47 were male and 53 were female; these subjects had a history of stroke due to CSVT, cardioembolics, or atrial fibrillation and had responded well to therapy. The research included 48 people who were using NOACs and 24 people who were taking warfarin. CONCLUSION:By summarizing the statistical data of our study we have observed that the total number of patients who were both on warfarin and NOAC's have same effectiveness in preventing stroke recurrence . The tolerability of all the drugs is almost same among the study population. The risk of having a recurrent stroke is more in patients with CSVT than that of patients with Atrial fibrillation and cardioembolism. Based on reviewing literatures and reference articles , the studies that have been carried out on NOAC's have shown that NOAC's are equally effective as warfarin and has an advantage of reduced complications like cerebral bleeding and has a fixed dosage regimen due to these advantages NOAC's can be used in place of warfarin. As there are limited number of samples the results may not be yet generalised. Further studies can be carried out on large scale population for more accurate evaluation